Literature DB >> 7779702

Adjuvant therapy for operable breast cancer; more answers, new questions.

T J Perren.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7779702      PMCID： PMC2033836          DOI： 10.1038/bjc.1995.223

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  4 in total

1.  Adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with axillary node-positive breast cancer: an update of the Guy's/Manchester trial.

Authors:  M A Richards; S M O'Reilly; A Howell; W D George; I S Fentiman; M A Chaudary; D Crowther; R D Rubens
Journal:  J Clin Oncol       Date:  1990-12       Impact factor: 44.544

2.  HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma.

Authors:  D C Allred; G M Clark; A K Tandon; R Molina; D C Tormey; C K Osborne; K W Gilchrist; E G Mansour; M Abeloff; L Eudey
Journal:  J Clin Oncol       Date:  1992-04       Impact factor: 44.544

3.  Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer.

Authors:  J N Ingle; J E Krook; S J Green; T P Kubista; L K Everson; D L Ahmann; M N Chang; H F Bisel; H E Windschitl; D I Twito
Journal:  J Clin Oncol       Date:  1986-02       Impact factor: 44.544

4.  c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer.

Authors:  H B Muss; A D Thor; D A Berry; T Kute; E T Liu; F Koerner; C T Cirrincione; D R Budman; W C Wood; M Barcos
Journal:  N Engl J Med       Date:  1994-05-05       Impact factor: 91.245
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.